Albeit to a lesser extent when compared to CRISPR/Cas9gRNA-mediated IL30 gene editing, nanoliposome-based delivery of CRISPR/Cas9gRNA-hIL30 complex dramatically inhibited the angiogenic potential of both PC cell lines, because it reshaped their transcriptional profiles and downregulated a wide range of proangiogenic genes, including ANGPTL 1/2/4, IL1β, CCL2, CXCL1, CXCL6, SERPINE1, SERPINF1, EFNB2, PLG, PF4, VEGFA, VEGFD, ANG, TGFβ1, EGF, and HGF, and a few negative regulators of vascular network formation, such as ADGRB1, COL18A1, CXCL10, and TIMP2 (Fig. 5d, e). The gene discussed is COL18A1; the disease is pachyonychia congenita.